ATS gains $20m; settles score with Carbomedics
This article was originally published in Clinica
Executive Summary
Cardiac surgery products manufacturer ATS Medical has strengthened its balance sheet after gaining $20m in equity financing from Essex Woodlands Health Ventures. Minneapolis, Minnesota-based ATS issued to Essex around 8.5 million shares of its common stock at a purchase price of $2.35 per share, and warrants to purchase over 2.5 million shares of common stock. The warrants are exercisableat $2.475 per share in the first year after the closing, $2.85 per share in the second year, and $3.10 thereafter. As part of the financing, Martin Sutter, Essex co-founder and managing director, has joined ATS' board of directors.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.